Avantor, INC 10-Q quarterly reports

Avantor, Inc. reported Q2 2026 results showing a slight increase in net sales driven by its VWR Distribution & Services segment, while the Bioscience & Medtech Products segment experienced a decline.

Avantor, Inc. reported flat net sales for the first quarter of 2026 compared to the prior year, with a 4.1% organic net sales decrease, while facing margin contractions due to inflationary pressures and higher costs.

Avantor, Inc. reported a significant net loss of $711.8 million for Q3 2025, primarily driven by a $785.0 million goodwill impairment charge, alongside declining sales and margins.

Avantor, Inc. reported a decline in net sales and net income for the second quarter and first half of 2025, primarily due to reduced customer demand and the divestiture of its Clinical Services business, despite progress on its cost transformation initiative.

Avantor reports a decrease in net sales for Q1 2025, impacted by reduced customer demand and a divestiture, while advancing its cost transformation initiative.

Avantor Inc. reported a slight decrease in net sales and a significant drop in net income for the third quarter of 2024, while also announcing the sale of its Clinical Services business.

Avantor's second quarter results show a decrease in net sales and adjusted operating income, alongside a cost transformation initiative aimed at significant savings.

Avantor's first quarter 2024 results show a decrease in net sales and profitability, driven by reduced customer demand and unfavorable product mix.